Dr. John A. Libertino
He is a renowned urologist who is highly regarded for his excellent clinical skills in treating patients with a variety of urologic diseases and is affiliated with Emerson Hospital in Concord, MA. His clinical interests include urologic surgery, adrenal cancer, renal cancer, bladder cancer, continent diversions, prostate cancer, urethral cancer and testes cancer.
Prior to joining Emerson, Dr. Libertino held several senior positions at Lahey Clinic Medical Center, including those as CEO and Chairman, Chairman of the Division of Surgery, Vice Chairman of the Board of Trustees and Director of the Sophia Gordon Cancer Center. Dr. Libertino completed his residency in urology at Yale-New Haven Medical Center and is a graduate of Georgetown University School of Medicine. He is board-certified in urology and surgery.
As a frequent contributor to medical journals, Dr. Libertino served as Editor-in-Chief of The American Journal of Urology Review. He has been honored with numerous awards throughout his career, including The Milton and Natalie Zucker Clinical Teaching Prize for Outstanding Clinical Teaching from Tufts University School of Medicine and the Lahey Clinical Medical Research Award. In addition to treating patients, Dr. Libertino has been named Senior Vice President of Clinical Business Development at Emerson Hospital.
Peter N. Madras, MD
Dr. Peter N. Madras received his MD from McGill University and enjoyed a 30 year career as a transplant and vascular surgeon and associate professor of surgery at Harvard Medical School before joining the staff of Lahey Hospital 12 years ago. Before becoming a surgeon, Dr. Madras was the Medical Program director at the Avco Everett Laboratory which produced the Intra-Aortic Balloon pump, the first temporarily implantable cardiac assist device which is still in use for treatment of heart failure.
During his surgical career Dr. Madras consulted to a number of device companies and was Medical Director at Grace Biomedical working on biohybrid artificial organs. Upon retiring from the active practice of surgery Dr. Madras founded two companies; the Medical Record Bank, Inc. and Asentral IRB, Inc. He was also principal investigator on a number of NIH SBIR grants devoted to the goal of advancing surgery without blood loss. He was appointed by the State Governor to serve on the Massachusetts Board of Registration in Medicine for 6 years, chairing that group for 2 years and followed that with service for two terms (six years) on the National Board of Medical Examiners. He was tasked by Harvard Medical International to assemble and lead a team to write the Regulations for the Practice of Medicine for the Dubai Healthcare City.
Currently, Dr. Madras is part of the core Faculty at the Sloan School of Business of MIT and serves on the boards of a number of young or start-up companies. Dr. Madras has been a member of MDG for 4 years and became President of MDG 18 months ago.
Professor Raj Persad – Urology
Professor Raj Persad has been a practising Uro-Oncology surgeon with an international reputation for innovation and research, since 1996. He specialises in Bladder, Prostate and Kidney Cancer. He has served on key National and International committees for guideline development, service reform and research such as the National Cancer Intelligence Network, National Cancer Research Institute, NIHR-RfPB, NICE, IBCG, BAUS Section of Oncology and Cancer Research UK.
He is one of the country’s leading pelvic cancer surgeons bringing with him advanced surgical techniques with him from his training abroad in the US and Europe. He leads an active research programme and is the recipient of £5m in research grants.
He has over 230 published scientific papers in urological cancer and 5 books.
He is a University examiner for higher degrees for London Oxford Cardiff and Bristol and has been an examiner for the College of Surgeons and Tutor in Surgical skills. He is a member of the Colorectal Health Technology Co-operative and is also the Lead Clinician in the Bristol Biomedical Research Unit prostate cancer programme.
He has been involved in drug discovery and development over the last 20 years as well as surgical device development. He is Chief and Principle Investigator for a number of NIHR portfolio clinical trials and has research interests in focal therapy of prostate cancer and novel therapies in castrate resistant prostate cancer and metastatic kidney cancer.
He is a key opinion leader in several areas of urology and, along with Professor David Gillatt, has established one of the country’s leading medical robotics programmes (Bristol Urological Institute in conjunction with the University of Bristol and the University of the West of England).
Uniquely, Professor Persad not only excels in cancer treatment and research but also has substantial experience in Andrological surgery and genital reconstruction as well as drug therapy used in the area of sexual and erectile dysfunction. He serves on the BAUS Section of Andrology as a National expert in this area.
RICHARD HINDLEY (Consultant Urological Surgeon)
Richard Hindley has had an exceptionally busy year following the NICE approval, in August 2018, of Rezum steam treatment for Benign Prostatic Hyperplasia (BPH). Richard is the lead surgeon in the UK for this pioneering new minimally invasive treatment. He continues to collate data on this treatment to monitor the efficacy and allow results to be followed and compared in medical trials.
In 2018, Richard received the honour of Visiting Professor of Knowledge Exchange for Winchester University in the Health and Wellbeing Research Group and was also recently appointed as a Specialist Adviser to NICE’s Interventional Procedures Programme.
Having qualified in Scotland at the University of Dundee, Richard spent his initial surgical training in Brighton before embarking on 6 years specialist Urology training based in the South Thames training region. This included 2 years at King’s Hospital before passing his final surgical exams and travelling to Brisbane for a laparoscopic urology fellowship in 2003.
He was later appointed as a consultant in Basingstoke in 2004. Since then he has spent the last 10 years developing the local service and his interests in minimally invasive treatments for urological conditions.
Richard is the clinical lead in Urology in his department at the North Hampshire Hospital. He has introduced cutting edge treatments including the first centre outside of London offering day case laser prostate surgery for BPH in 2005. He is also a recognised expert in prostate cancer diagnosis and focal treatment using technologies such as HIFU and Cryotherapy. Basingstoke is now one of the leading centres in the UK and receives referrals from across the South of England. He has very much been at the forefront of treatments for benign and malignant conditions of the prostate.
He is also a very experienced laparoscopic renal surgeon and is now using the Da Vinci robot for the treatment of kidney conditions.
Richard enjoys teaching and training and has helped to introduce laparoscopy, HIFU and Greenlight laser surgery to centres around the UK. He has a large research portfolio and is currently recruiting over 50 patients per year to prostate related clinical trials.
Professor Hashim Ahmed
He is currently Chair of Urology at Imperial College London. Hashim is an internationally renowned expert in prostate cancer diagnosis, imaging and biopsy as well as minimally invasive therapies for prostate cancer such as HIFU and cryotherapy – either whole-gland or focal therapy for primary prostate cancer or radiorecurrent disease. He has taught dozens of surgeons in these techniques in the UK and around the world and given numerous invited international lectures in this area. He has an extensive research portfolio with about £6M in grant income as a principal applicant and co-applicant to a research programme of approximately £14M. He has published over 150 peer-reviewed papers in areas that have led to key changes in the way we diagnose and treat men with localised prostate cancer. He currently holds a £2.1M Wellcome Trust Senior Clinical Research Fellowship and is Director of the Wellcome Trust Prostate Research in Imaging and Surgical Methodology (PRISM) Programme.
Hashim qualified from the University of Oxford where he attended St Peters College and Linacre College. Whilst he was a student he was awarded the William Osler Prize in Medicine. He then held house office posts in Queen Elizabeth Hospital, Birmingham and University Hospitals Manchester before returning to Oxford for an Anatomy Prosector post. Hashim then held senior house jobs in surgery on the Royal Free Hospital, London rotation followed by specialist registrar posts at West Middlesex Hospital, Charing Cross Hospital/Imperial College, University College Hospital and Watford General Hospital as part of the Imperial College Urology Rotation.
He was a Pelican Cancer Foundation Research Fellow followed by a MRC Clinician Research Training fellowship at University College London at which time a number of imaging and focal therapy trials were started. His research interests are in Health Technology Evaluation including multi-parametric MRI, Histoscanning, Tissue Type Imaging, as well as therapeutic interventions such as high intensity focused ultrasound, irreversible electroporation, photodynamic therapy, cryotherapy and radiofrequency ablation. He has completed numerous phase I/II clinical trials evaluating the role of focal therapy in prostate cancer and is lead PI and Co-PI in a number of multicentre trials including the UK NIHR-HTA funded study NCRN PROMIS study evaluating the role of multi-parametric MRI in men with a raised PSA using Template Prostate Mapping as the reference standard as well as NCRN INDEX, a multicentre focal therapy study using HIFU with 3 year follow-up and NCRN FORECAST. He previously held a £1.2M MRC Clinician Scientist Fellowship for 5 years and currently holds a £2M Senior Clinical Research Fellowship from the Wellcome Trust. His total grant income is £5M as lead applicant and £8M in total as co-applicant.
He has been visiting professor to UCLA, Tokyo, Weill-Cornell and Detroit universities and has given over 30 plenary lectures at national and international urology, oncology and imaging meetings.
The team he led recently was awarded the BMJ/BMA Innovation Award 2015 and the Health Services Journal Acute Sector Innovation Award 2016.
He holds a number of committee positions:
– Chair, ICTU-Surgery Trials Forum
– Member, Executive Committee for European Association of Urology Research Foundation
– Chair, Localised Disease Subgroup, NCRI Prostate Clinical Studies Group
– Member, NCRI Screening Prevention Early Diagnosis (SPED) Group
– Consulting Editor in Imaging, British Journal of Urology International
– Editorial Board, European Urology
Professor Hashim U. Ahmed qualified from the University of Oxford where he attended St Peter’s College and Linacre College. Whilst he was a student he was awarded the William Osler Prize in Medicine. He then held house office posts in Queen Elizabeth Hospital, Birmingham and University Hospital Manchester before returning to Oxford for an anatomy prosector post. Prof Ahmed then held senior house jobs in surgery on the Royal Free Hospital London rotation followed by specialist registrar posts at West Middlesex Hospital, Charing Cross Hospital and Imperial College London, University College Hospital and Watford General Hospital as part of the Imperial College urology rotation.
He is one of London’s leading urological surgeons. Operating from the Imperial College Healthcare NHS Trust and the BUPA Cromwell Hospital he is best known for his role in the pioneering of ground-breaking changes regarding how men are diagnosed and treated with prostate cancer as well as the minimally invasive therapy of benign prostate enlargement (BPH). He is a leading expert in transperineal targeted and image fusion prostate biopsy as well as focal HIFU and cryotherapy. He is one of the top two surgeons offering Rezum water vapour or steam therapy for enlarged prostates in the UK.
Professor Ahmed is dedicated to research for which he has won several prestigious awards and has given numerous lectures on field-related matters. He is renowned for the focal therapy prostate treatments that he provides which offer a less risky alternative to traditional surgery and radiotherapy and he is a global authority on MRI and minimally invasive diagnosis methods.
Mr Rick Popert MS FRCS (Urology)
Rick Popert was appointed as a consultant in 1996 having completed his higher surgical training at Guy’s Hospital and urological research at King’s College Hospital. Mr Popert’s clinical expertise is in the comprehensive evalulation and surgical treatment of benign and malignant prostatic disease.
He has successfully transferred his experience from conventional open radical prostatectomy to the robotic assisted approach. He has carried out over 600 robotic prostatectomies since 2006.
He has the UK’s largest experience of single visit dynamic intra-operative prostate brachytherapy and has carried out over 800 of these cases since 2004, with Dr Stephen Morris and Dr Ronald Beaney, Consultant Clinical Oncologists.
He is an expert in Precision Prostate Diagnostics and has developed a rapid access prostate MRI assessment service with Dr Giles Rottenberg, Consultant Radiologist, along with a unique systematic transperineal biopsy approach which provides accurate tumour localisation, an approach that has been further enhanced by the technique of MRI fusion targeted biopsy of the prostate which he introduced in March 2012.
For benign prostatic disease, he has one of the UK’s largest experience of holmium laser prostatectomy (HoLEP). He has carried out over 800 holmium laser enucleations with reduced bleeding and length of stay in patients with prostate volumes larger than 100 cc compared with standard transurethral prostatectomy (TURP).
In 2014 he introduced a prostate arterial embolisation service in association Dr Tarun Sabharwal, Consultant Interventional Radiologist. This is an alternative to the surgical management of benign prostatic disease avoiding the complications of urinary incontinence, erectile and ejaculatory dysfunction.
Mark Gregory Garzotto, MD
Dr. Mark Garzotto is a urologist affiliated with OHSU Hospital and the Portland VA Medical Center and is practicing in Portland, OR. Dr. Garzotto has over 30 years of experience in the medical field and specializes in diseases of the urinary tract and the male reproductive system. This includes areas of the bladder, urethra, kidneys, penis and prostate.
Dr. Garzotto’s career in medicine began in 1990, when he graduated with his Medical Degree from the Louisiana State Univ School of Medicine In New Orleans, New Orleans, LA . After medical school, Mark Gregory Garzotto MD completed residency at Univ Of Fl College Of Medicine, Urology and General Surgery. Dr. Garzotto is board certified in Urology by the American Board of Urology.